AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03106766
Drug: Acne cream 1X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily application of facial acne cream 1X after facial cleansing
Trial: NCT03056599
Drug: Multiple drug microinjection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
Trial: NCT04876807
Drug: ACP-196
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In Parts 1, 2, and 3, participants will receive oral Dose 1 of ACP-196 (reference or acidic formulation as applicable) on Day 1, Day 3, Day 8, and Day 10.
Trial: NCT00561093
Drug: Placebo pill imitating pentoxiphylline
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill imitating pentoxiphylline 400 mg daily, to imitate the anti-inflammatory and appetite-stimulating pill while subjects undergo thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
Trial: NCT02622334
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo formulation will be administered in Part A.
Trial: NCT02622334
Drug: RO5093151
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO5093151 is a ophthalmic solution, available in dose strengths as 0.1%, 0.5% and 1%.
Trial: NCT01533129
Drug: Testosterone 250mg injection
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The testosterone 250mg ester IM injections performed in three weeks.
Trial: NCT03094663
Drug: Bupivacaine with epinephrine
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.5% with epinephrine 30cc
Trial: NCT04637009
Drug: TAS1553
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form: tablet; Route of Administration: oral
Trial: NCT03224598
Drug: A-101 Topical Solution 40%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A-101 Topical Solution 40%
Trial: NCT04254042
Drug: Perindopril Arginine
RxNorm normalized name: Perindopril Arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Perindopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
Trial: NCT01910597
Drug: SBG
RxNorm normalized name: PSBG - Pregnancy specific beta 1-glycoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04254042
Drug: Zofenopril, Calcium Salt, (1(R*),2Alpha,4Alpha)-isomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg Zofenopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
Trial: NCT00140361
Drug: lumefantrine plus artemether
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02533505
Drug: Matching Placebo pMDI 160/4.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given according at the same dose and schedule as the active comparator - cross-over design.
Trial: NCT01254994
Drug: Traditional comprehensive medical treatment
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bed rest, sufficient energy and vitamins, reduced glutathione, prostaglandin E1, hepatocyte growth factor (HGF), plasma and albumin, maintenance of water and electrolyte balance, and prevention and treatment of complications, such as infections, hepatic encephalopathy, hemorrhage, hepatorenal syndrome and ascites.
Trial: NCT04175509
Drug: Rectal acetaminophen
RxNorm normalized name: acetaminophen Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal 1300mg
Trial: NCT04175509
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 1000mg
Trial: NCT02484859
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion will be started with a bolus dose of 0.5 µg/kg before the induction, and will be continued throughout the surgery at a dose of 0.25-0.5 µg/kg/min. At the end of the surgery, the rate of infusion will be decreased to 0.05 µg/kg/min, and continued until the patient is extubated.
Trial: NCT04061057
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: 1. Normal saline Intravenous normal saline bolus of immediately after anesthesia induction followed by infusion up to 1 hr after end of surgery. Volume of normal saline is equal to lidocaine.~2. Fentanyl IV infusion via PCA (patient controlled analgesia) machine of fentanyl 10 μg/ml, ramosetron 0.3 mg, normal saline, total 100 ml, infusion rate 1 ml/hr, 1 ml bolus and lockout time 7 min.
Trial: NCT00893867
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.
Trial: NCT04144218
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group will be given oral placebo supplementation on the basis of the original antiepileptic drugs.
Trial: NCT00730028
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CLINDA (adult dose of 300 mg three times daily; pediatric dose of 25-30 mg/kg/day divided three times daily up to a maximum dose of 900 mg/day). Study drug will be administered for 10 days.
Trial: NCT02172183
Drug: Psychopharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methylphenidate or atomoxetine
Trial: NCT00172094
Drug: NPS 1776 (800 mg)
RxNorm normalized name: NP Thyroid Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPS 1776 (800 mg) powder
Trial: NCT00172094
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in non-carbonated fruit flavored drink (150 ml)
Trial: NCT01284231
Drug: MEDI-565
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-565 will be administered by IV infusion
Trial: NCT01284231
Drug: MEDI-565
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 subjects with selected gastrointestinal tumor type to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
Trial: NCT01284231
Drug: MEDI-565
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 Subjects with refractory Gastroesophageal cancer to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
Trial: NCT00523887
Drug: Fentanyl transdermal therapeutic system
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01225237
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01864226
Drug: RO5545965
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending doses
Trial: NCT01864226
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending doses
Trial: NCT03336645
Drug: SHP615
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).
Trial: NCT01351909
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02561923
Drug: Kcentra, a 4-factor PCC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kcentra, a 4-factor PCC, 50 IU/kg, single dose, intravenously administered (maximum rate of 210 \[international units\] IU/min) on Day 4.
Trial: NCT03596060
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl will be used for introduction in both regional and general anesthesia. It will also be used for general anesthesia maintenance.
Trial: NCT04034095
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants enrolled in this study will continue to receive prednisolone in combination with abiraterone along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
Trial: NCT02307565
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
Trial: NCT00613054
Drug: Zactima, Gleevec, Hydroxyurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pts will start treatment on day 1 of cycle 1 w Zactima, imatinib mesylate \& hydroxyurea. All 3 agents administered in continuous daily, oral manner. Imatinib mesylate dose 400 mg/day for pts not on EIAEDs \& 1000 mg/day for pts on EIAEDs based on previous studies demonstrating that pts on EIAEDs require significantly higher doses of imatinib mesylate \& that such doses are safe \& well tolerated. Dose of hydroxyurea 500 mg twice day. Dose level of Zactima will be increased in successive cohorts of pts as described below.~Cohorts of 3-6 pts will accrue at each dose level until MTD is defined. Each cohort will consist of a mini of 3 newly enrolled pts. Intra-patient dose escalation is not permitted. Cohorts may be expanded at any dose level for further elaboration of safety \& pharmacokinetic parameters as required.~Treatment cycle is defined as daily administration of Zactima + imatinib mesylate \& hydroxyurea for 28 days for purpose of scheduling evaluations.
Trial: NCT01701843
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily topical treatment for 14 days
Trial: NCT03121989
Drug: Hyperpolarized Pyruvate (13C) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The new imaging method being tested in this study is called Metabolic MRI, which provides pictures of the metabolism occurring within cancer cells. It also involves injection of a contrast medicine, Hyperpolarized Pyruvate (13C) Injection, into the arm vein. The Participants in the active comparator arm will be injected with study drug Hyperpolarized Pyruvate (13C) Injection at a dose of 0.43/ml/kg.
Trial: NCT03794999
Drug: Exposure to other asthma medications
RxNorm normalized name: zinc pyrithione Medicated Liquid Soap [Born To Be Mild]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to asthma medications for any number of days, at any dose, and at any time from LMP up to the date of enrollment, but no exposure to benralizumab during pregnancy or within 8 weeks prior to LMP.
Trial: NCT01547780
Drug: [11C]PBR28 and Positron Emission Tomography (PET)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brain PET with \[11C\]PBR28. 11C\]PBR28 is a new PET ligand that images TSPO with high levels of specific binding.
Trial: NCT02108366
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 200mg daily
Trial: NCT00280111
Drug: I321
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose of I321 10\^5 FFu
Trial: NCT00280111
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 crystal of potassium permanganate dissolved in the bicarbonate buffer to colour match the vaccine
Trial: NCT04522336
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04365907
Drug: Zafatek tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly new anti-diabetic drug approved only in Japan
Trial: NCT01366365
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04078087
Drug: Non obese
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After standard anesthesia monitoring, Administration of oxygen was performed for 3 minutes with 10 L/min fresh gas flow of 100% oxygen. After oxygen administration, 25% of (2 mg/kg) total propofol dose was injected over 3-5 seconds (Propofol Lipuro 1%, B. Braun Melsungen AG, Germany). The patients were observed and asked immediately whether they had pain in the arm, its VAS score, type of pain (burning, parathesia or other) and its onset was documented (to differentiate early or late type of pain).
Trial: NCT04078087
Drug: Obese.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After standard anesthesia monitoring, Administration of oxygen was performed for 3 minutes with 10 L/min fresh gas flow of 100% oxygen. After oxygen administration, 25% of (2 mg/kg) total propofol dose was injected over 3-5 seconds (Propofol Lipuro 1%, B. Braun Melsungen AG, Germany). The patients were observed and asked immediately whether they had pain in the arm, its VAS score, type of pain (burning, parathesia or other) and its onset was documented (to differentiate early or late type of pain).
Trial: NCT02555683
Drug: QAW039
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QAW039 150 mg once daily
Trial: NCT02555683
Drug: QAW039
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QAW039 450 mg once daily
Trial: NCT02555683
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily
Trial: NCT02576002
Drug: Assigned pulmonary hypertension medication
RxNorm normalized name: Antihypertensives for pulmonary arterial hypertension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As assigned by treating physician; may include following product classes: - Calcium channel blockers/antagonists - Prostanoids (prostaglandins, thromboxanes, prostacyclines) - Endothelin receptor antagonists - PDE-5 inhibitors - SGc stimulators
Trial: NCT00003594
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003594
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04316065
Drug: YHP1906
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YHP1906 Tab. 5 mg
Trial: NCT04316065
Drug: YHR1902
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator. YHR1902 Tab. 5 mg
Trial: NCT01415284
Drug: Hydroxyethylstarch 130/0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: first patient : 500 mL. Following volumes according to up-down sequential allocation, with increments or decrements of 100 mL. An absence of hypotension will lead to an decrement while a presence of hypotension will result in an increment.
Trial: NCT03865706
Drug: Placebo Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250cc sterile water alone, given twice daily a sweetener is added to the water to create identical flavor
Trial: NCT00603590
Drug: Placebo drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive tablet Once a day Identical in appearance to intervention drug
Trial: NCT04493515
Drug: Oral Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo orally (24 IU)
Trial: NCT03865706
Drug: Broad-spectrum antibiotics
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care treatment for infections
Trial: NCT02685020
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline, 0.5 mL injection administered intramuscularly.
Trial: NCT05152004
Drug: Klaricid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg and amoxicillin 1 g bid. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg bid. for 7 days
Trial: NCT00916292
Drug: FGF-1 141
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. Low dose: FGF-1, 0.3 mg per square centimeter.
Trial: NCT01288976
Drug: Medical Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Non-Surgical Medically Managed Heart Failure (HF) Group consists of patients with mitral regurgitation (MR) in whom the MR is managed non-surgically based on standard hospital clinical practice. Patients with MR who receive a pacemaker, Implantable Cardiac Defibrillator (ICD) and/or Cardiac Resynchronization Therapy (CRT) treatments may be included
Trial: NCT00916292
Drug: FGF-1 141
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. High dose: FGF-1, 3.0 mg per square centimeter.
Trial: NCT01111929
Drug: Counseling for LAM+ LNG-EC
RxNorm normalized name: Viril Lam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: They will be provided by the above proper LAM counseling and contraceptive counseling. Additionally, they will be provided by EC pills and advised to use these pills if one of the prerequisites of LAM expires and sexual relation with their husband had occurred before the initiation of another long term contraceptive. Each women in this group will be supplied with one packet containing two 0.75 mg Levonorgestrel EC pills and advised to swallow the two tablets as soon as possible after having sexual intercourse with their husband after the expiry of LAM. They will be informed that they should not use the method after more than 5 days of having intercourse.~They will be also advised not to use EC pills more than once. All women who have used the EC pills need to visit the clinic within few days of use for contraception advice. All the above information will be additionally given to the patient in a small flyer.
Trial: NCT02218476
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00913861
Drug: standard sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard sedation: fentanyl 2x0,5 microg/kg at beginning of procedure and propofol PCS: 20mg bolus than 10mg/bolus, lock-out = 0.
Trial: NCT00817687
Drug: mycophenolate mofetil [CellCept]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed; + early biopsy
Trial: NCT00817687
Drug: mycophenolate mofetil [CellCept]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed; + standard treatment
Trial: NCT01490723
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg/m2 by vein on Day +1, +3 and +6. Patients receiving an unrelated graft will also be given methotrexate on Day +11 after the transplant.
Trial: NCT01876433
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04215003
Drug: CL4
RxNorm normalized name: Mills CL43 MLS 16,20DR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR6390（CDK4/6 inhibitor）125 mg qd(three week on one week off); oral letrozole 2.5 mg daily； Adebrelimab was given intravenously, 600mg each time, once every 2 weeks; Premenopause：Goserelin 3.6mg IM IM Q4W.
Trial: NCT02713256
Drug: CFZ533
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFZ533 intravenously over approximately one hour
Trial: NCT01124630
Drug: CS-1008
RxNorm normalized name: MyoGesic-CS
DrugBank: GCS-100 (DB17566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-1008 will be administered IV each week. The initial/loading dose (6 mg/kg) will be administered Day 1 of Cycle 1. Maintenance doses of 2 mg/kg will be administered weekly thereafter.
Trial: NCT01124630
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The FOLFIRI regimen will be administered IV at Weeks 1 and 3 of each 4 week cycle, and it will begin at Week 1 of Cycle 1. It will comprise irinotecan, 180 mg/m2 IV infusion over 30 to 120 minutes; leucovorin, 400 mg/m2 IV infusion to match the duration of the irinotecan infusion; and 5-FU, 400 mg/m2 (bolus) followed by 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46 to 48 hours continuous infusion).
Trial: NCT02493894
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo each 8 hours for 24 hours
Trial: NCT01992159
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT02582359
Drug: MLN9708
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of 1.5 mg or 2.3 mg or 3.0 mg taken by mouth on days 2, 5, 9, 12 of each cycle.
Trial: NCT01698138
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 transurethral injections, each of 1 ml solution containing NaCl.
Trial: NCT02669277
Drug: IVIG prepared by minipool technology
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: To demonstrate the efficacy of new product IVIG prepared by minipool technology as assessed by Bleeding Score and platelet count at 3 days, 1 week, 2 weeks and 4 weeks.
Trial: NCT02669277
Drug: standard IVIG product
RxNorm normalized name: standardized senna concentrate Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: to compare efficacy and safety with the minipool IVIG
Trial: NCT06335901
Drug: Drug:Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary Intervention
Trial: NCT01902524
Drug: Fentanyl-TTS
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All of the participants will receive the study drug at least once transdermally, administration dosage starts at 12.5 microgram/hour.